Aveo signs BI to manufacture PhII candidate ficlatuzumab
This article was originally published in Scrip
Executive Summary
Cancer therapeutic developer Aveo Pharmaceuticals has entered into an agreement with Boehringer Ingelheim for large-scale process development and clinical manufacturing of its second most advanced product candidate, ficlatuzumab, which is currently in Phase II clinical development in patients with non-small cell lung cancer. The compound is an antibody that binds to hepatocyte growth factor, a ligand that is thought to play a role in tumour growth.